deltatrials
Completed PHASE3 NCT00042029

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-073)

A Double-Blind, Multicenter, Placebo-Controlled Study of MK0869 in the Treatment of Patients With Major Depressive Disorder

Sponsor: Merck Sharp & Dohme LLC

Conditions Major Depressive Disorder
Interventions Comparator: placebo MK0869, aprepitant
Updated 7 times since 2017 Last updated: May 2, 2017 Started: Jun 18, 2002 Primary completion: Oct 3, 2003 Completion: Oct 3, 2003

Listed as NCT00042029, this PHASE3 trial focuses on Major Depressive Disorder and remains completed. Sponsored by Merck Sharp & Dohme LLC, it has been updated 7 times since 2002, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jun 2022 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jun 2022 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 2 earlier versions

  1. Jun 2017 — Jun 2018 [monthly]

    Completed PHASE3

  2. Jan 2017 — Jun 2017 [monthly]

    Completed PHASE3

    First recorded

Jun 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Merck Sharp & Dohme LLC
Data source: Merck Sharp & Dohme LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.